---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-019326"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:35:49.441750+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM

## Summary
- RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.
- PKP2 protein expression increased ~110% and ~398% from baseline in 2 patients with low expression.
- Improved RV function, KCCQ-12 scores (34-41 points), and NYHA class (II to I) in patients.
- PVCs reduced 9-63%; NSVT episodes eliminated in one patient. No further dose escalation.

## SEC filing metadata
- accession: 0001140361-25-019326
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/0001140361-25-019326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/ef20049151_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-019326
- JSON: https://secwatch.observer/filing/0001140361-25-019326.json
- Plain text: https://secwatch.observer/filing/0001140361-25-019326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.